NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.33 -0.08 (-0.09%) GOLD FUTURES
2,405.70 +22.70 (+0.95%) DOW
37,798.97 +63.86 (+0.17%) Bitcoin GBP
50,516.72 -368.75 (-0.72%)
BioArctic AB (publ) (0RV2.IL)
| Previous close | 202.70 |
| Open | 201.20 |
| Bid | 193.20 x 0 |
| Ask | 213.40 x 0 |
| Day's range | 199.30 - 204.60 |
| 52-week range | 196.30 - 391.00 |
| Volume | |
| Avg. volume | 12,072 |
| Market cap | 20.337B |
| Beta (5Y monthly) | -0.23 |
| PE ratio (TTM) | 66.22 |
| EPS (TTM) | 3.07 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 May 2019 |
| 1y target est | N/A |
PR NewswireLecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the European Medicines Agency (EMA), did not take place due to procedural reasons at EMA.
PR NewswireSales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
BioArctic AB's (publ) (STO: BIOA-B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2023 (third quarter of Eisai's fiscal year, ending March 2024). In total, sales of JPY 1.1 billion were recorded in the period, resulting in a royalty to BioArctic amounting to SEK 7.3 million.
PR NewswireThe European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Scientific Advisory Group (SAG) will convene to discuss the Marketing Authorisation Application (MAA) of lecanemab (generic name, brand name: Leqembi®), which is currently under review by the European Medicines Agency (EMA). The meeting of the SAG is expected to take place during the first quarter of 2024.
